Literature DB >> 22198308

Breaking the loop: oxytocin as a potential treatment for drug addiction.

Iain S McGregor1, Michael T Bowen.   

Abstract

Drug use typically occurs within a social context, and social factors play an important role in the initiation, maintenance and recovery from addictions. There is now accumulating evidence of an interaction between the neural substrates of affiliative behavior and those of drug reward, with a role for brain oxytocin systems in modulating acute and long-term drug effects. Early research in this field indicated that exogenous oxytocin administration can prevent development of tolerance to ethanol and opiates, the induction of stereotyped, hyperactive behavior by stimulants, and the withdrawal symptoms associated with sudden abstinence from drugs and alcohol. Additionally, stimulation of endogenous oxytocin systems is a key neurochemical substrate underlying the prosocial and empathogenic effects of party drugs such as MDMA (Ecstasy) and GHB (Fantasy). Brain oxytocin systems exhibit profound neuroplasticity and undergo major neuroadaptations as a result of drug exposure. Many drugs, including cocaine, opiates, alcohol, cannabis, MDMA and GHB cause long-term changes in markers of oxytocin function and this may be linked to enduring deficits in social behavior that are commonly observed in laboratory animals repeatedly exposed to these drugs. Very recent preclinical studies have illustrated a remarkable ability of exogenously delivered oxytocin to inhibit stimulant and alcohol self-administration, to alter associated drug-induced changes in dopamine, glutamate and Fos expression in cortical and basal ganglia sites, and to prevent stress and priming-induced relapse to drug seeking. Oxytocin therefore has fascinating potential to reverse the corrosive effects of long-term drugs abuse on social behavior and to perhaps inoculate against future vulnerability to addictive disorders. The results of clinical studies examining intranasal oxytocin effects in humans with drug use disorders are eagerly awaited. This article is part of a Special Issue entitled Oxytocin, Vasopressin, and Social Behavior.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22198308     DOI: 10.1016/j.yhbeh.2011.12.001

Source DB:  PubMed          Journal:  Horm Behav        ISSN: 0018-506X            Impact factor:   3.587


  93 in total

1.  Oxytocin and the social brain: beware the complexity.

Authors:  Andreas Bartels
Journal:  Neuropsychopharmacology       Date:  2012-07       Impact factor: 7.853

Review 2.  Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models.

Authors:  Megan M Yardley; Lara A Ray
Journal:  Addict Biol       Date:  2016-02-01       Impact factor: 4.280

Review 3.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

4.  Role of oxytocin in the ventral tegmental area in social reinforcement.

Authors:  Johnathan M Borland; Kymberly N Grantham; Lauren M Aiani; Kyle J Frantz; H Elliott Albers
Journal:  Psychoneuroendocrinology       Date:  2018-05-21       Impact factor: 4.905

5.  Oxytocin Reduces Cigarette Consumption in Daily Smokers.

Authors:  Kathryne Van Hedger; Meredith J Kushner; Royce Lee; Harriet de Wit
Journal:  Nicotine Tob Res       Date:  2019-05-21       Impact factor: 4.244

6.  Activation of oxytocin receptors, but not arginine-vasopressin V1a receptors, in the ventral tegmental area of male Syrian hamsters is essential for the reward-like properties of social interactions.

Authors:  Zhimin Song; Johnathan M Borland; Tony E Larkin; Maureen O'Malley; H Elliott Albers
Journal:  Psychoneuroendocrinology       Date:  2016-09-09       Impact factor: 4.905

7.  Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention.

Authors:  Brian J Sherman; Nathaniel L Baker; Aimee L McRae-Clark
Journal:  Psychiatry Res       Date:  2017-01-20       Impact factor: 3.222

Review 8.  Concurrent Treatment of Substance Use and PTSD.

Authors:  Julianne C Flanagan; Kristina J Korte; Therese K Killeen; Sudie E Back
Journal:  Curr Psychiatry Rep       Date:  2016-08       Impact factor: 5.285

9.  Intranasal oxytocin dampens cue-elicited cigarette craving in daily smokers: a pilot study.

Authors:  Melissa A Miller; Anya Bershad; Andrea C King; Royce Lee; Harriet de Wit
Journal:  Behav Pharmacol       Date:  2016-12       Impact factor: 2.293

Review 10.  Influence of stress associated with chronic alcohol exposure on drinking.

Authors:  Howard C Becker
Journal:  Neuropharmacology       Date:  2017-04-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.